Naringenin
Based on 23 publication(s) in Google Scholar
Naringenin is the predominant flavanone in Citrus reticulata Blanco; displays strong anti-inflammatory and antioxidant activities. Naringenin has anti-dengue virus (DENV) activity.
For research use only. We do not sell to patients.
- Purity: 99.28%
- CAS No.: 480-41-1
- Formula: C15H12O5
- Molecular Weight:272.25
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Naringenin
More- Nat Immunol. 2025 Apr 11. [Abstract]
- Nat Commun. 2025 Aug 21;16(1):7810. [Abstract]
- Food Chem. 2025 May 31:489:144992. [Abstract]
- Phytomedicine. 2025 May:140:156484. [Abstract]
- Phytomedicine. 2024 Sep:132:155886. [Abstract]
- New Phytol. 2025 Dec 7. [Abstract]
- Arch Pharm Res. 2025 Apr 2. [Abstract]
- Biomed Pharmacother. 2023 Aug:164:114902. [Abstract]
- J Ethnopharmacol. 2026 May 23:363:121417. [Abstract]
- Biofactors. 2022 Jan;48(1):190-203. [Abstract]
- Int J Mol Sci. 2026 Feb 5;27(3):1576. [Abstract]
- Microb Cell Fact. 2025 Jul 2;24(1):153. [Abstract]
- Pharm Biol. 2025 Dec;63(1):1-10. [Abstract]
- BMC Plant Biol. 2025 Feb 12;25(1):185. [Abstract]
- Poult Sci. 2025 May 2;104(8):105257. [Abstract]
- J Funct Foods. 2020 Jun.
- Neurochem Res. 2024 Nov 18;50(1):17. [Abstract]
- Heliyon. 2024 Aug 2;10(16):e35489. [Abstract]
- Int J Med Sci. 2025 Jan 1;22(1):110-120. [Abstract]
- Environ Toxicol. 2022 Aug;37(8):1840-1852. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- Biochem Biophys Res Commun. 2018 Sep 3;503(1):297-303. [Abstract]
- Int J Insect Sci. 2018 Feb 28:10:1179543318758409. [Abstract]
-
Histological Imaging/Staining
-
In Vivo Efficacy Study
-
Bio/Physico-chemical Assay
-
WB
-
Bio/Physico-chemical Assay
All Endogenous Metabolite Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>100 μM
Compound: 4
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 18440233] |
| B16-BL6 | IC50 |
>100 μM
Compound: 4
|
Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
|
[PMID: 18440233] |
| BJ | EC50 |
>10 μM
Compound: 2
|
Cytotoxicity against human BJ cells assessed as viable cells after 72 hrs by calcein AM assay
Cytotoxicity against human BJ cells assessed as viable cells after 72 hrs by calcein AM assay
|
[PMID: 20192247] |
| C8166 | CC50 |
141.6 μg/mL
Compound: 6
|
Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
[PMID: 24794743] |
| C8166 | EC50 |
9.47 μg/mL
Compound: 6
|
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis
|
[PMID: 24794743] |
| CCRF-CEM | EC50 |
>10 μM
Compound: 2
|
Cytotoxicity against human CEM cells assessed as viable cells after 72 hrs by calcein AM assay
Cytotoxicity against human CEM cells assessed as viable cells after 72 hrs by calcein AM assay
|
[PMID: 20192247] |
| Col2 | EC50 |
>1 x 103 nM
Compound: naringenin
|
Cytotoxicity against human Col2 cells
Cytotoxicity against human Col2 cells
|
[PMID: 15043407] |
| DLD-1 | IC50 |
>25 μM
Compound: 9
|
Cytotoxicity against human DLD1 cells
Cytotoxicity against human DLD1 cells
|
[PMID: 18039011] |
| H9 | EC50 |
92 μM
Compound: 19
|
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
|
[PMID: 8158164] |
| H9 | IC50 |
294 μM
Compound: 19
|
Cytotoxicity against human H9 cells after 3 days
Cytotoxicity against human H9 cells after 3 days
|
[PMID: 8158164] |
| HEK293 | IC50 |
14.4 μM
Compound: 12
|
Inhibition of human recombinant 17beta-HSD2 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol
Inhibition of human recombinant 17beta-HSD2 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol
|
[PMID: 18533708] |
| HEK293 | IC50 |
4.96 μM
Compound: 12
|
Inhibition of human recombinant 17beta-HSD1 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol
Inhibition of human recombinant 17beta-HSD1 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol
|
[PMID: 18533708] |
| HeLa | IC50 |
>25 μM
Compound: 9
|
Cytotoxicity against human HeLa cells
Cytotoxicity against human HeLa cells
|
[PMID: 18039011] |
| HeLa | IC50 |
>100 μM
Compound: 4
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 18440233] |
| HeLa | EC50 |
>10 μM
Compound: 2
|
Cytotoxicity against human HeLa cells assessed as viable cells after 72 hrs by calcein AM assay
Cytotoxicity against human HeLa cells assessed as viable cells after 72 hrs by calcein AM assay
|
[PMID: 20192247] |
| HL-60 | IC50 |
413.7 μM
Compound: Naringenin
|
Cytotoxicity against human HL60 cells after 46 hrs by MTT assay
Cytotoxicity against human HL60 cells after 46 hrs by MTT assay
|
[PMID: 23756061] |
| HSC-2 | CC50 |
0.55 mM
Compound: 19
|
Cytotoxicity against human HSC2 cells
Cytotoxicity against human HSC2 cells
|
[PMID: 11170668] |
| HT-1080 | IC50 |
>100 μM
Compound: 4
|
Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
|
[PMID: 18440233] |
| HUVEC | ED50 |
>1 x 103 nM
Compound: naringenin
|
Cytotoxicity against HUVEC
Cytotoxicity against HUVEC
|
[PMID: 15043407] |
| Jurkat | IC50 |
41.6 μM
Compound: Naringenin
|
Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method
Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method
|
[PMID: 30776692] |
| Jurkat | IC50 |
48.8 μM
Compound: Naringenin
|
Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method
Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method
|
[PMID: 30776692] |
| KB | ED50 |
>1 x 103 nM
Compound: naringenin
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 15043407] |
| KB | ED50 |
2.71 μg/mL
Compound: narigenin
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 8450317] |
| L5178Y | IC50 |
≥11.3 μM
Compound: 1
|
Cytotoxicity against multi-drug resistant mouse L5178Y cells transfected with ABCB1 gene assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Cytotoxicity against multi-drug resistant mouse L5178Y cells transfected with ABCB1 gene assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 33038666] |
| L5178Y | IC50 |
≥11.3 μM
Compound: 1
|
Cytotoxicity against parental mouse L5178Y cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Cytotoxicity against parental mouse L5178Y cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 33038666] |
| Lewis lung carcinoma cell line | IC50 |
>100 μM
Compound: 4
|
Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay
Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay
|
[PMID: 18440233] |
| LNCaP | ED50 |
>1 x 103 nM
Compound: naringenin
|
Cytotoxicity against human LNCAP cells
Cytotoxicity against human LNCAP cells
|
[PMID: 15043407] |
| Lu1 | ED50 |
>1 x 103 nM
Compound: naringenin
|
Cytotoxicity against human Lu1 cells
Cytotoxicity against human Lu1 cells
|
[PMID: 15043407] |
| MCF7 | EC50 |
>10 μM
Compound: 2
|
Cytotoxicity against human MCF7 cells assessed as viable cells after 72 hrs by calcein AM assay
Cytotoxicity against human MCF7 cells assessed as viable cells after 72 hrs by calcein AM assay
|
[PMID: 20192247] |
| MCF7 | IC50 |
5.1 μM
Compound: Naringenin
|
Inhibition of aromatase in human MCF7 cells using [1beta-3H]androstenedione as substrate measured after 1 hr by liquid scintillation counting method
Inhibition of aromatase in human MCF7 cells using [1beta-3H]androstenedione as substrate measured after 1 hr by liquid scintillation counting method
|
[PMID: 27155469] |
| MCF7 | IC50 |
0.3 μM
Compound: Naringenin
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay
|
[PMID: 33257172] |
| NALM-6 | IC50 |
426.3 μM
Compound: Naringenin
|
Cytotoxicity against human NALM6 cells after 46 hrs by MTT assay
Cytotoxicity against human NALM6 cells after 46 hrs by MTT assay
|
[PMID: 23756061] |
| Neutrophil | IC50 |
3.3 μM
Compound: 66
|
Inhibition of fMLF/CB-induced human Neutrophil activation assessed as reduction in superoxide anion
Inhibition of fMLF/CB-induced human Neutrophil activation assessed as reduction in superoxide anion
|
[PMID: 37683361] |
| Neutrophil | IC50 |
5.3 μM
Compound: 66
|
Inhibition of fMLF/CB-induced human Neutrophil activation assessed as reduction in elastase release
Inhibition of fMLF/CB-induced human Neutrophil activation assessed as reduction in elastase release
|
[PMID: 37683361] |
| PLC-PRF-5 | ED50 |
2.47 μg/mL
Compound: narigenin
|
Cytotoxicity against human PLC/PRF/5 cells
Cytotoxicity against human PLC/PRF/5 cells
|
[PMID: 8450317] |
| RAW264.7 | IC50 |
60 μM
Compound: 11
|
Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells measured after 16 hrs
Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells measured after 16 hrs
|
[PMID: 27955927] |
| RPMI-8226 | EC50 |
>10 μM
Compound: 2
|
Cytotoxicity against human RPMI8226 cells assessed as viable cells after 72 hrs by calcein AM assay
Cytotoxicity against human RPMI8226 cells assessed as viable cells after 72 hrs by calcein AM assay
|
[PMID: 20192247] |
| TERT-RPE1 | ED50 |
>1 x 103 nM
Compound: naringenin
|
Cytotoxicity against human telomerase reverse transcriptase expressing human RPE1 cells
Cytotoxicity against human telomerase reverse transcriptase expressing human RPE1 cells
|
[PMID: 15043407] |
| THP-1 | EC50 |
>10 μM
Compound: 2
|
Cytotoxicity against human THP1 cells after 72 hrs by erythosin B staining method
Cytotoxicity against human THP1 cells after 72 hrs by erythosin B staining method
|
[PMID: 20192247] |
| THP-1 | IC50 |
>10 μM
Compound: 25
|
Cytotoxicity against human THP1 cells assessed as cell viability after 24 hrs by WST assay
Cytotoxicity against human THP1 cells assessed as cell viability after 24 hrs by WST assay
|
[PMID: 25735399] |
| U-266 | EC50 |
>10 μM
Compound: 2
|
Cytotoxicity against human U266 cells assessed as viable cells after 72 hrs by calcein AM assay
Cytotoxicity against human U266 cells assessed as viable cells after 72 hrs by calcein AM assay
|
[PMID: 20192247] |
| WM-115 | IC50 |
524.8 μM
Compound: Naringenin
|
Cytotoxicity against human WM115 cells after 46 hrs by MTT assay
Cytotoxicity against human WM115 cells after 46 hrs by MTT assay
|
[PMID: 23756061] |
Naringenin is shown to inhibit the proliferation of HepG2 cells resulted partly from an accumulation of cells in the G0/G1 and G2/M phase of the cell cycle. Naringenin has been shown to induce apoptosis as evidenced by nuclei damage and increased proportion of apoptotic cells. Naringenin triggers the mitochondrial-mediated apoptosis pathway as shown by an increased ratio of Bax/Bcl-2, subsequent release of cytochrome C, and sequential activation of caspase-3[1]. Naringenin exposure significantly reduces the cell viability of A431 cells with a concomitant increase in nuclear condensation and DNA fragmentation in a dose dependent manner. Cell cycle study shows that naringenin induced cell cycle arrest in G0/G1 phase of cell cycle and caspase-3 analysis reveal a dose dependent increment in caspase-3 activity which leads to cell apoptosis[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 480-41-1
-
Appearance Solid
-
Molecular Weight 272.25
-
Formula C15H12O5
-
Color White to light yellow
-
SMILES
O=C1C[C@@H](C2=CC=C(O)C=C2)OC3=CC(O)=CC(O)=C13
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (23)
-
Journal Impact Factor
-
Most Recent
-
Nat Immunol
2025 Apr 11. PMID: 40217111 -
Nat Commun
Flavonoid pathway intermediates implicate UVR8 in functions beyond canonical UV-B signaling. [Abstract]2025 Aug 21;16(1):7810. PMID: 40841532 -
Food Chem
Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]2025 May 31:489:144992. PMID: 40466530 -
Phytomedicine
Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]2025 May:140:156484. PMID: 40090046 -
Phytomedicine
Investigating the potential mechanism and therapeutic effects of SLXG for cholesterol gallstone treatment. [Abstract]2024 Sep:132:155886. PMID: 39059092
Naringenin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Sep:132:155886. [Abstract]
Naringenin (100 mg/kg/d, i.g.). HE staining, Oil red staining in the liver.
Naringenin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Sep:132:155886. [Abstract]
Naringenin (100 mg/kg/d, i.g.). The appearance of gallstones of mice in different treatment groups.
Naringenin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Sep:132:155886. [Abstract]
The naringenin l group and the naringenin H group were treated with naringenin (50 mg/kg/d, i.g.) and naringenin (100 mg/kg/d, i.g.). CGS column chart for mice.
Naringenin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Sep:132:155886. [Abstract]
The naringenin l group and the naringenin H group were treated with naringenin (50 mg/kg/d, i.g.) and naringenin (100 mg/kg/d, i.g.). WB results and statistical analysis bar graphs of HMGCR, UGT1A1, and SOAT2 (n = 6).
Naringenin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Sep:132:155886. [Abstract]
The naringenin l group and the naringenin H group were treated with naringenin (50 mg/kg/d, i.g.) and naringenin (100mg/kg/d, i.g.). Levels of ALT and AST in serum.
-
New Phytol
Transcription factor SlJIG orchestrates multi-layer defense in tomato against the invasive pest Phthorimaea absoluta. [Abstract]2025 Dec 7. PMID: 41355216 -
Arch Pharm Res
The inhibition of endothelial DLL4-NOTCH1 signaling by 2'-hydroxyflavanone enhances anti-PD-1 therapy in melanoma. [Abstract]2025 Apr 2. PMID: 40172769 -
Biomed Pharmacother
Guiqi Baizhu prescription ameliorates cytarabine-induced intestinal mucositis by targeting JAK2 to inhibit M1 macrophage polarization. [Abstract]2023 Aug:164:114902. PMID: 37209628 -
J Ethnopharmacol
Simo Tang mitigates mitochondria-dependent apoptosis via PI3K/AKT pathway activation in Chronic atrophic gastritis. [Abstract]2026 May 23:363:121417. PMID: 41765119 -
Biofactors
Naringenin protects swine testis cells from bisphenol A-induced apoptosis via Keap1/Nrf2 signaling pathway. [Abstract]2022 Jan;48(1):190-203. PMID: 34914851 -
Int J Mol Sci
Dual Targeting of HIF-1α and DLL4 by Isoxanthohumol Potentiates Immune Checkpoint Blockade. [Abstract]2026 Feb 5;27(3):1576. PMID: 41683994 -
Microb Cell Fact
2025 Jul 2;24(1):153. PMID: 40605049 -
Pharm Biol
Naringenin inhibits ferroptosis to reduce radiation-induced lung injury: insights from network Pharmacology and molecular docking. [Abstract]2025 Dec;63(1):1-10. PMID: 39969099 -
BMC Plant Biol
Transcriptomic, metabonomic and proteomic analyses reveal that terpenoids and flavonoids are required for Pinus koraiensis early defence against Bursaphelenchus xylophilus infection. [Abstract]2025 Feb 12;25(1):185. PMID: 39934660 -
Poult Sci
Naringenin as a phytogenic adjuvant systematically enhances the protective efficacy of H9N2 inactivated vaccine through coordinated innate-adaptive immune priming in chickens. [Abstract]2025 May 2;104(8):105257. PMID: 40344923 -
Naringenin purchased from MedChemExpress. Usage Cited in: J Funct Foods. 2020 Jun.
Naringenin decreases the number of Iba-1-positive microglia and fully-activated microglia. Schematic diagram of the selected region of brain section for immunochemistry and Representative Iba-1 staining.
Naringenin purchased from MedChemExpress. Usage Cited in: J Funct Foods. 2020 Jun.
Naringenin prevents the neuroinflammation. Representative Western blot bands of TNF-α, IL-1β, IL-6, IL-10, and iNOS.
-
Neurochem Res
Naringenin Protected Against Blood Brain Barrier Breakdown after Ischemic Stroke through GSK-3β/ β-Catenin Pathway. [Abstract]2024 Nov 18;50(1):17. PMID: 39556287 -
Heliyon
Integrating network analysis and experimental validation to reveal the mechanism of si-jun-zi decoction in the treatment of renal fibrosis. [Abstract]2024 Aug 2;10(16):e35489. PMID: 39220912 -
Int J Med Sci
Naringenin Mitigates Dasatinib-Induced Kidney Damage by Modulating Antioxidant Defense, Inflammation, and Apoptosis Pathways. [Abstract]2025 Jan 1;22(1):110-120. PMID: 39744177 -
Environ Toxicol
Dibutyl phthalate-induced oxidative stress and apoptosis in swine testis cells and therapy of naringenin via PTEN/PI3K/AKT signaling pathway. [Abstract]2022 Aug;37(8):1840-1852. PMID: 35363423 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Biochem Biophys Res Commun
Effects of intracellular iron overload on cell death and identification of potent cell death inhibitors. [Abstract]2018 Sep 3;503(1):297-303. PMID: 29890135 -
Int J Insect Sci
Do Bioflavonoids in Juniperus virginiana Heartwood Stimulate Oviposition in the Ladybird Coleomegilla maculata?. [Abstract]2018 Feb 28:10:1179543318758409. PMID: 29531477
Solvent & Solubility
DMSO : ≥ 100 mg/mL (367.31 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Naringenin is dissolved in DMSO and diluted in cell culture medium. The cells are rinsed with PBS and grown in a medium containing various concentrations of naringenin (50, 100, 150, 200, 250, 300 μM). The solvent DMSO treated cells are served as control. After 24 hrs of treatment, the medium is removed and replaced by another medium containing MTT. Cell viability is measured using the MTT assay[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Rats: Semi-purified, powdered diets are prepared for concentrations of naringenin: 0, 0.003, 0.006, and 0.012% of diet. After 7 days of acclimatization, rats are assigned to one of four groups, with six animals per group, and fed semi-purified experimental diets for 6 weeks. The experimental diets contain 16% fat, 45.5% sucrose, and different naringenin concentration (0, 0.003, 0.006, or 0.012%) (Table 1). Rats have ad libitum access to food and water during the study period. Food intake and body weight are measured throughout the experiment[3].
Mouse: Eight- to 12-week-old mice are fed ad libitum a rodent standard diet or a high-fat diet containing 42% of calories from fat plus cholesterol (0.05% wt/wt). Naringenin is added to the Western diet at 1 or 3% (wt/wt). Ldlr−/− mice are fed for 4 weeks and C57BL/6J mice for 30 weeks. Food intake is measured daily, and body weight is measured biweekly. Mice are fasted for 6 h before intervention[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Arul D, et al. Naringenin (citrus flavonone) induces growth inhibition, cell cycle arrest and apoptosis in human hepatocellular carcinoma cells. Pathol Oncol Res. 2013 Oct;19(4):763-70. [Content Brief]
[2]. Ahamad MS, et al. Induction of apoptosis and antiproliferative activity of naringenin in human epidermoid carcinomacell through ROS generation and cell cycle arrest. PLoS One. 2014 Oct 16;9(10):e110003. [Content Brief]
[3]. Cho KW, et al. Dietary naringenin increases hepatic peroxisome proliferators-activated receptor α proteinexpression and decreases plasma triglyceride and adiposity in rats. Eur J Nutr. 2011 Mar;50(2):81-8. [Content Brief]
[4]. Mulvihill EE, et al. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDLreceptor-null mice with diet-induced insulin resistance. Diabetes. 2009 Oct;58(10):2198-210. [Content Brief]
[5]. Chen S, et al. Naringenin inhibits TNF-α induced VSMC proliferation and migration via induction of HO-1. Food Chem Toxicol. 2012 Sep;50(9):3025-31. [Content Brief]
[6]. Frabasile S, et al. The citrus flavanone naringenin impairs dengue virus replication in human cells. Sci Rep. 2017 Feb 3;7:41864. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.6731 mL | 18.3655 mL | 36.7309 mL | 91.8274 mL |
| 5 mM | 0.7346 mL | 3.6731 mL | 7.3462 mL | 18.3655 mL | |
| 10 mM | 0.3673 mL | 1.8365 mL | 3.6731 mL | 9.1827 mL | |
| 15 mM | 0.2449 mL | 1.2244 mL | 2.4487 mL | 6.1218 mL | |
| 20 mM | 0.1837 mL | 0.9183 mL | 1.8365 mL | 4.5914 mL | |
| 25 mM | 0.1469 mL | 0.7346 mL | 1.4692 mL | 3.6731 mL | |
| 30 mM | 0.1224 mL | 0.6122 mL | 1.2244 mL | 3.0609 mL | |
| 40 mM | 0.0918 mL | 0.4591 mL | 0.9183 mL | 2.2957 mL | |
| 50 mM | 0.0735 mL | 0.3673 mL | 0.7346 mL | 1.8365 mL | |
| 60 mM | 0.0612 mL | 0.3061 mL | 0.6122 mL | 1.5305 mL | |
| 80 mM | 0.0459 mL | 0.2296 mL | 0.4591 mL | 1.1478 mL | |
| 100 mM | 0.0367 mL | 0.1837 mL | 0.3673 mL | 0.9183 mL |